RAMSES Laboratory, Rizzoli RIT-Research, Innovation & Technology Department, Istituto di Ricerca Codivilla Putti, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano, 1/10, 40136 Bologna, Italy.
Int J Mol Sci. 2024 Aug 29;25(17):9356. doi: 10.3390/ijms25179356.
The management of rheumatic diseases has noticeably changed in recent years with the development of targeted therapeutic agents, namely, biological disease-modifying antirheumatic drugs. Identifying essential signaling pathways and factors crucial for the development and progression of these diseases remains a significant challenge. Therapy could be used to delay the onset or reduce harm. The endocannabinoid system's presence within the synovium can be identified as a suggested target for therapeutic interventions due to its role in modulating pain, inflammation, and joint metabolism. This review brings together the most pertinent information concerning the actions of the endocannabinoid system present in inflamed synovial tissue and its interaction with phytocannabinoids and synthetic cannabinoids, which can be used from a therapeutic perspective to minimize the inflammatory and pain processes typical of osteoarthritis and rheumatoid arthritis.
近年来，随着靶向治疗药物（即生物靶向改善病情抗风湿药）的发展，风湿性疾病的治疗发生了显著变化。确定对这些疾病的发生和发展至关重要的基本信号通路和因素仍然是一个重大挑战。治疗可以用于延缓发病或减轻危害。由于内源性大麻素系统在调节疼痛、炎症和关节代谢方面的作用，其在滑膜中的存在可以被认为是治疗干预的一个潜在靶点。这篇综述汇集了有关炎症性滑膜组织中内源性大麻素系统的作用及其与植物大麻素和合成大麻素相互作用的最相关信息，从治疗角度来看，这些作用可以最小化骨关节炎和类风湿关节炎的炎症和疼痛过程。
